Doxycycline treatment decreases morbidity and mortality of murine neurocysticercosis: Evidence for reduction of apoptosis and matrix metalloproteinase activity

American Journal of Pathology

Volumn 175, Issue 2, 2009, Pages 685-695

  Alvarez, Jorge I ^a,b,c   Krishnamurthy, Janani ^b   Teale, Judy M ^a,b,d  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 16; NEUTROPHIL COLLAGENASE; STROMELYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HOST; INFLAMMATION; LEUKOCYTE; MORBIDITY; MORTALITY; MOUSE; NERVE CELL; NEUROCYSTICERCOSIS; NONHUMAN; PARENCHYMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SURVIVAL;

EID: 68449096480     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.081073     Document Type: Article

References (55)

1. Del Brutto OH, Santibanez R, Idrovo L, Rodriguez S, Diaz-Calderon E, Navas C, Gilman RH, Cuesta F, Mosquera A, Gonzalez AE, Tsang VC, Garcia HH: Epilepsy and neurocysticercosis in Atahualpa: a door-to-door survey in rural coastal Ecuador. Epilepsia 2005, 46:583-587
2. Garcia HH, Del Brutto OH: Neurocysticercosis: updated concepts about an old disease. Lancet Neurol 2005, 4:653-661
3. Montano SM, Villaran MV, Ylquimiche L, Figueroa JJ, Rodriguez S, Bautista CT, Gonzalez AE, Tsang VC, Gilman RH, Garcia HH: Neurocysticercosis: association between seizures, serology, and brain CT in rural Peru. Neurology 2005, 65:229-233
4. White AC, Jr: Neurocysticercosis: updates on epidemiology, pathogenesis, diagnosis, and management. Annu Rev Med 2000, 51:187-206
5. Garcia HH, Gonzalez AE, Evans CA, Gilman RH: Taenia solium cysticercosis. Lancet 2003, 362:547-556
6. Ridaura C: Cysticercosis: present state of knowledge and perspectives. New York, Academic Press, 1982, pp 107-231
7. Nash TE, Neva FA: Recent advances in the diagnosis and treatment of cerebral cysticercosis. N Engl J Med 1984, 311:1492-1496
8. White AC, Jr., Robinson P, Kuhn R: Taenia solium cysticercosis: host-parasite interactions and the immune response. Chem Immunol 1997, 66:209-230
9. Carpio A: Neurocysticercosis: an update. Lancet Infect Dis 2002, 2:751-762
10. Restrepo BI, Llaguno P, Sandoval MA, Enciso JA, Teale JM: Analysis of immune lesions in neurocysticercosis patients: central nervous system response to helminth appears Th1-like instead of Th2. J Neuroimmunol 1998, 89:64-72
11. Restrepo BI, Alvarez JI, Castano JA, Arias LF, Restrepo M, Trujillo J, Colegial CH, Teale JM: Brain granulomas in neurocysticercosis patients are associated with a Th1 and Th2 profile. Infect Immun 2001, 69:4554-4560
12. Ransohoff RM, Kivisakk P, Kidd G: Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003, 3:569-581
13. Engelhardt B, Ransohoff RM: The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005, 26:485-495
14. Alvarez JI, Teale JM: Breakdown of the blood brain barrier and blood-cerebrospinal fluid barrier is associated with differential leukocyte migration in distinct compartments of the CNS during the course of murine NCC. J Neuroimmunol 2006, 173:45-55
15. Alvarez JI, Teale JM: Multiple expression of matrix metalloproteinases in murine neurocysticercosis: implications for leukocyte migration through multiple central nervous system barriers. Brain Research 2008, 1214:145-158
16. Baker AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115:3719-3727
17. McCawley LJ, Matrisian LM: Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000, 6:149-156
18. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516
19. Anthony DC, Miller KM, Fearn S, Townsend MJ, Opdenakker G, Wells GM, Clements JM, Chandler S, Gearing AJ, Perry VH: Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS. J Neuroimmunol 1998, 87:62-72
20. Alvarez JI, Teale JM: Evidence for differential changes of junctional complex proteins in murine neurocysticercosis dependent upon CNS vasculature. Brain Res 2007, 1169:98-111
21. Agrawal S, Anderson P, Durbeej M, van Rooijen N, Ivars F, Opdenakker G, Sorokin LM: Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med 2006, 203:1007-1019
22. Alvarez JI, Teale JM: Differential changes in junctional complex proteins suggest the ependymal lining as the main source of leukocyte infiltration into ventricles in murine neurocysticercosis. J Neuroimmunol 2007, 187:102-113
23. Leppert D, Waubant E, Galardy R, Bunnett NW, Hauser SL: T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995, 154:4379-4389
24. Rosenberg GA, Yang Y: Vasogenic edema due to tight junction disruption by matrix metalloproteinases in cerebral ischemia. Neurosurg Focus 2007, 22:E4
25. Lee HM, Golub LM, Cao J, Teronen O, Laitinen M, Salo T, Zucker S, Sorsa T: CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. Curr Med Chem 2001, 8:257-260
26. Meli DN, Coimbra RS, Erhart DG, Loquet G, Bellac CL, Tauber MG, Neumann U, Leib SL: Doxycycline reduces mortality and injury to the brain and cochlea in experimental pneumococcal meningitis. Infect Immun 2006, 74:3890-3896
27. Wong ET, Alsop D, Lee D, Tam A, Barron L, Bloom J, Gautam S, Wu JK: Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas. Cerebrospinal Fluid Res 2008, 5:1
28. Yim CW, Flynn NM, Fitzgerald FT: Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother 1985, 28:347-348
29. Burggraf D, Trinkl A, Dichgans M, Hamann GF: Doxycycline inhibits MMPs via modulation of plasminogen activators in focal cerebral ischemia. Neurobiol Dis 2007, 25:506-513
30. Cardona AE, Restrepo BI, Jaramillo JM, Teale JM: Development of an animal model for neurocysticercosis: immune response in the central nervous system is characterized by a predominance of gamma delta T cells. J Immunol 1999, 162:995-1002
31. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, Lin E, Yang GY, Young WL: Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab 2006, 26:1157-1164
32. Hasnain SE, Begum R, Ramaiah KV, Sahdev S, Shajil EM, Taneja TK, Mohan M, Athar M, Sah NK, Krishnaveni M: Host-pathogen interactions during apoptosis. J Biosci 2003, 28:349-358
33. Hidalgo J, Aschner M, Zatta P, Vasak M: Roles of the metallothionein family of proteins in the central nervous system. Brain Res Bull 2001, 55:133-145
34. Wiese L, Kurtzhals JA, Penkowa M: Neuronal apoptosis, metallothionein expression and proinflammatory responses during cerebral malaria in mice. Exp Neurol 2006, 200:216-226
35. Penkowa M: Metallothioneins are multipurpose neuroprotectants during brain pathology. Febs J 2006, 273:1857-1870
36. Rosenberg GA, Estrada E, Kelley RO, Kornfeld M: Bacterial collagenase disrupts extracellular matrix and opens blood-brain barrier in rat. Neurosci Lett 1993, 160:117-119
37. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM: The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol 1999, 9:1441-1447
38. Davies JE, Wang L, Garcia-Oroz L, Cook LJ, Vacher C, O'Donovan DG, Rubinsztein DC: Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 2005, 11:672-677
39. Copin JC, Goodyear MC, Gidday JM, Shah AR, Gascon E, Dayer A, Morel DM, Gasche Y: Role of matrix metalloproteinases in apoptosis after transient focal cerebral ischemia in rats and mice. Eur J Neurosci 2005, 22:1597-1608
40. Gary DS, Mattson MP: Integrin signaling via the PI3-kinase-Akt pathway increases neuronal resistance to glutamate-induced apoptosis. J Neurochem 2001, 76:1485-1496
41. Gu Z, Cui J, Brown S, Fridman R, Mobashery S, Strongin AY, Lipton SA: A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005, 25:6401-6408
42. Sugawara T, Chan PH: Reactive oxygen radicals and pathogenesis of neuronal death after cerebral ischemia. Antioxid Redox Signal 2003, 5:597-607
43. Kang YJ: The antioxidant function of metallothionein in the heart. Proc Soc Exp Biol Med 1999, 222:263-273
44. Blaauwgeers HG, Sillevis Smitt PA, De Jong JM, Troost D: Distribution of metallothionein in the human central nervous system. Glia 1993, 8:62-70
45. Carrasco J, Giralt M, Penkowa M, Stalder AK, Campbell IL, Hidalgo J: Metallothioneins are upregulated in symptomatic mice with astrocyte-targeted expression of tumor necrosis factor-alpha. Exp Neurol 2000, 163:46-54
46. Penkowa M, Carrasco J, Giralt M, Moos T, Hidalgo J: CNS wound healing is severely depressed in metallothionein I- and II-deficient mice. J Neurosci 1999, 19:2535-2545
47. Vela JM, Hidalgo J, Gonzalez B, Castellano B: Induction of metallothionein in astrocytes and microglia in the spinal cord from the myelin-deficient jimpy mouse. Brain Res 1997, 767:345-355
48. Krizbai IA, Bauer H, Bresgen N, Eckl PM, Farkas A, Szatmari E, Traweger A, Wejksza K, Bauer HC: Effect of oxidative stress on the junctional proteins of cultured cerebral endothelial cells. Cell Mol Neurobiol 2005, 25:129-139
49. Lenzser G, Kis B, Snipes JA, Gaspar T, Sandor P, Komjati K, Szabo C, Busija DW: Contribution of poly(ADP-ribose) polymerase to post-ischemic blood-brain barrier damage in rats. J Cereb Blood Flow Metab 2007, 27:1318-1326
50. Romanic AM, Madri JA: Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol 1994, 4:145-156
51. Yong VW, Power C, Forsyth P, Edwards DR: Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001, 2:502-511
52. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T: Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 1998, 12:12-26
53. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM: Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004, 24:733-738
54. Roach DM, Fitridge RA, Laws PE, Millard SH, Varelias A, Cowled PA: Up-regulation of MMP-2 and MMP-9 leads to degradation of type IV collagen during skeletal muscle reperfusion injury; protection by the MMP inhibitor, doxycycline. Eur J Vasc Endovasc Surg 2002, 23:260-269
55. Hagberg L, Palmertz B, Lindberg J: Doxycycline and pyrimethamine for toxoplasmic encephalitis. Scand J Infect Dis 1993, 25:157-160